Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep Maria Piulats

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal for Immunotherapy of Cancer|December 29, 2022
Biomarkers of tumor-reactive CD4<sup>+</sup> and CD8<sup>+</sup> TILs associate with improved prognosis in endometrial cancerJara Palomero, Carla Panisello, Maria Lozano-Rabella, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 11, 2026
A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitorsFerran Medina-Jover, Agnès Figueras, Núria Gendrau-Sanclemente, et al.
The Lancet. Oncology|February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Chris Parker, Fred Saad, et al.
Cancer Epidemiology|June 26, 2019
Defining a mutational signature for endometrial cancer screening and early detectionLaura Costas, Luis Palomero, Yolanda Benavente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2019
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerElena Castro, Nuria Romero-Laorden, Angela Del Pozo, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal for Immunotherapy of Cancer|December 29, 2022
Biomarkers of tumor-reactive CD4<sup>+</sup> and CD8<sup>+</sup> TILs associate with improved prognosis in endometrial cancerJara Palomero, Carla Panisello, Maria Lozano-Rabella, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 11, 2026
A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitorsFerran Medina-Jover, Agnès Figueras, Núria Gendrau-Sanclemente, et al.
The Lancet. Oncology|February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Chris Parker, Fred Saad, et al.
Cancer Epidemiology|June 26, 2019
Defining a mutational signature for endometrial cancer screening and early detectionLaura Costas, Luis Palomero, Yolanda Benavente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2019
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerElena Castro, Nuria Romero-Laorden, Angela Del Pozo, et al.
Pageof 3